Page last updated: 2024-09-04

cyc 682 and Neoplasms

cyc 682 has been researched along with Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choudhary, AK; Fleming, IN; Green, SR1
Kantarjian, H; Liu, X; Plunkett, W1
Diaz, I; Muggia, F; Peters, GJ1
Braich, TA; Burch, PA; Camoriano, JK; Delaunoit, T; Erlichman, C; Kaur, JS; Kobayash, T; Reid, JM; Rubin, J1
Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M1

Reviews

1 review(s) available for cyc 682 and Neoplasms

ArticleYear
Sapacitabine for cancer.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:4

    Topics: Animals; Arabinonucleosides; Cell Cycle; Clinical Trials as Topic; Cytosine; DNA Damage; Drug Evaluation, Preclinical; Humans; Neoplasms; Prodrugs; Randomized Controlled Trials as Topic

2012

Trials

1 trial(s) available for cyc 682 and Neoplasms

ArticleYear
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
    Investigational new drugs, 2006, Volume: 24, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cytosine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms

2006

Other Studies

3 other study(ies) available for cyc 682 and Neoplasms

ArticleYear
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
    British journal of cancer, 2010, Oct-26, Volume: 103, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Death; Cell Line, Tumor; Cytosine; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Neoplasms; Vorinostat; Xenograft Model Antitumor Assays

2010
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Cytosine; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Nucleosides

2012
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
    British journal of cancer, 2007, Sep-03, Volume: 97, Issue:5

    Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids

2007